Bio-Techne Corp (TECH)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account
Sell

$49.50

Buy

$52.13

arrow-up$1.03 (+2.11%)

Bio-Techne Corp and is a biotechnology company which develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products.
Prices updated at 09 May 2025, 12:00 BST
| Prices minimum 15 mins delay
|
Prices in USD
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Robert V. Baumgartner, C.P.A.
CEO
Mr. Kim Kelderman
Most recent earnings
30 Jun 2024
Fiscal year end
30 Jun 2024
Employees
3,100
Head office
614 McKinley Place N.E.
Minneapolis
United States
55413
mobile
+1 612 379-8854
letter
-

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Dr. Roeland Nusse,PhD
Independent Director
0.09m--0.29m-
Dr. Amy Herr, PhD
Independent Director
-----
Mr. John L. Higgins
Independent Director
0.10m--0.30m-
Dr. Joseph D. Keegan, PhD
Independent Director
0.08m--0.28m-
Mr. Robert V. Baumgartner, C.P.A.
Chairman of the Board
0.21m--0.41m-
Ms. Julie L. Bushman
Independent Director
0.09m--0.29m-
Mr. James T. Hippel
Principal Accounting Officer, Executive Vice President and Chief Financial Officer
0.70m--5.20m-
Dr. Rupert Vessey, B.M.,D.Phil.,F.R.C.P.,M.A.
Independent Director
0.08m--0.28m-
Dr. Alpna Seth, PhD
Independent Director
0.08m--0.28m-
Mr. Kim Kelderman
President, Chief Executive Officer and Director
0.76m--6.85m-
Dr. Judith Klimovsky, M.D.
Independent Director
0.01m--0.11m-
Mr. William Geist
President, Protein Sciences
0.55m--3.65m-
Dr. Matthew McManus
President, Diagnostics and Genomics Segment
0.25m--1.99m-
Mr. Shane Bohnen
Senior Vice President, General Counsel and Corporate Secretary
0.34m--1.46m-

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
Vanguard Group Inc18,594,6080.023332756441.50469230 Apr 202511.76
BlackRock Inc14,036,4940.020461972191.42506730 Apr 20258.88
BlackRock, Inc.13,843,281-13843281-30 Apr 20258.71
T. Rowe Price Associates, Inc.10,654,2670.08847122995413.05086130 Apr 20256.74
T Rowe Price Associates, Inc9,424,313-9424313-30 Apr 20255.93

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
01 Nov 2024-Mr. James T. Hippel--13,159--
01 Nov 2024-Mr. James T. Hippel75.31487,632106,610--
01 Nov 2024-Mr. James T. Hippel--113,085--
01 Nov 2024-Mr. James T. Hippel--34,634--
01 Nov 2024-Mr. Kim Kelderman75.31183,00339,004--
01 Nov 2024-Mr. William Geist--9,911--
01 Nov 2024-Mr. William Geist75.31246,26411,081--
01 Nov 2024-Mr. William Geist--14,351--
24 Oct 2024-Mr. John L. Higgins--3,511--
24 Oct 2024-Mr. John L. Higgins--48,196--
24 Oct 2024-Dr. Joseph D. Keegan, PhD--3,511--
24 Oct 2024-Dr. Joseph D. Keegan, PhD--13,771--
24 Oct 2024-Mr. Robert V. Baumgartner, C.P.A.--3,511--
24 Oct 2024-Mr. Robert V. Baumgartner, C.P.A.--44,863--
24 Oct 2024-Dr. Roeland Nusse,PhD--3,511--
24 Oct 2024-Dr. Roeland Nusse,PhD--44,559--
24 Oct 2024-Ms. Julie L. Bushman--7,135--
24 Oct 2024-Ms. Julie L. Bushman--3,511--
24 Oct 2024-Dr. Rupert Vessey, B.M.,D.Phil.,F.R.C.P.,M.A.--3,511--
24 Oct 2024-Dr. Rupert Vessey, B.M.,D.Phil.,F.R.C.P.,M.A.--9,347--
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.